[topsearch__bar__shortcode]

June 2021

RCON stock

SenesTech, Inc. (SNES) Stock Surge Following Continued Proliferation of ContraPest

SenesTech, Inc. (SNES) stock prices were up by 4.40% as of the market closing on June 25th, 2021, bringing the price per share up to USD$1.66 at the end of the trading day. Subsequent pre-market fluctuations saw the stock surge by another 7.23%, bringing it up to USD$1.78. New Brand Campaign May 2021 saw the

SenesTech, Inc. (SNES) Stock Surge Following Continued Proliferation of ContraPest Read More »

GLG Stock

How Has The Trevena (TRVN) Stock Declined 13% In Extended Trades?

In after-hours trading, shares of Trevena Inc. (TRVN) were down -12.76% on Friday. The stock closed the previous trading session up 2.62% or $0.05 at $1.96. The stock fluctuated between $1.93 and $2.00 throughout the day. A total of 22.49 million shares were exchanged, more than TRVN’s 50-day volume of 3.41 million as well as

How Has The Trevena (TRVN) Stock Declined 13% In Extended Trades? Read More »

EZFL Stock

What Happened To Make NeuBase (NBSE) Stock Surge 10% After Hours?

NeuBase Therapeutics Inc. (NBSE) closed Friday’s after-hours trading at $5.87, up 9.72%. NeuBase’s stock price finished last trading session up 5.31% at $5.35. A range of $4.96-$5.39 was observed for NBSE stock. NBSE stock traded 2.29 million shares, which was above its daily average of 0.34 million shares over 100 days. The NBSE’s shares have

What Happened To Make NeuBase (NBSE) Stock Surge 10% After Hours? Read More »

RCON stock

CTI BioPharma Corp. (CTIC) Stock Trends Higher Following Progress in Commercialization of Pacritinib

CTI BioPharma Corp. (CTIC) stock prices stayed stable over the course of the trading day on June 25th, 2021. After-hours trading saw the stock climb by 6.84%, bringing it up to USD$2.50. Pacritinib Progress The company recently announced progress in their goal of providing pacritinib to myelofibrosis patients with thrombocytopenia, with current treatments leaving a

CTI BioPharma Corp. (CTIC) Stock Trends Higher Following Progress in Commercialization of Pacritinib Read More »